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Tumor	microenvironments	feature	immune	inhibitory	mechanisms	that	prevent	T	cells	from	generating	effec-
tive	antitumor	immune	responses.	Therapeutic	interventions	aimed	at	disrupting	these	inhibitory	mecha-
nisms	have	been	shown	to	enhance	antitumor	immunity,	but	they	lack	direct	cytotoxic	effects.	Here,	we	inves-
tigated	the	effect	of	cytotoxic	cancer	chemotherapeutics	on	immune	inhibitory	pathways.	We	observed	that	
exposure	to	platinum-based	chemotherapeutics	markedly	reduced	expression	of	the	T	cell	inhibitory	molecule	
programmed	death	receptor-ligand	2	(PD-L2)	on	both	human	DCs	and	human	tumor	cells.	Downregulation	of	
PD-L2	resulted	in	enhanced	antigen-specific	proliferation	and	Th1	cytokine	secretion	as	well	as	enhanced	rec-
ognition	of	tumor	cells	by	T	cells.	Further	analysis	revealed	that	STAT6	controlled	downregulation	of	PD-L2.	
Consistent	with	these	data,	patients	with	STAT6-expressing	head	and	neck	cancer	displayed	enhanced	recur-
rence-free	survival	upon	treatment	with	cisplatin-based	chemoradiation	compared	with	patients	with	STAT6-
negative	tumors,	demonstrating	the	clinical	relevance	of	platinum-induced	STAT6	modulation.	We	therefore	
conclude	that	platinum-based	anticancer	drugs	can	enhance	the	immunostimulatory	potential	of	DCs	and	
decrease	the	immunosuppressive	capability	of	tumor	cells.	This	dual	action	of	platinum	compounds	may	
extend	their	therapeutic	application	in	cancer	patients	and	provides	a	rationale	for	their	use	in	combination	
with	immunostimulatory	compounds.
Introduction
Recently, it has become evident that chemotherapeutic drugs not 
only have a direct cytotoxic effect on tumor cells but may also 
potentiate the immune system via so-called off-target effects (1, 
2). For example, direct immune-activating effects of cancer che-
motherapy have been observed: treatment with low concentra-
tions of several chemotherapeutics resulted in increased antigen 
cross-presentation, T lymphocyte expansion, and T cell infiltra-
tion of tumors by to-date-unknown molecular mechanisms 
(3, 4). In addition, the cytotoxic drug oxaliplatin was shown 
to induce an immunogenic type of cell death in a TLR4/high-
mobility group box 1–dependent manner (5, 6). However, the 
effect of treatment with cancer chemotherapeutics on immune 
inhibitory pathways that play a crucial role in tumor immune 
escape is unknown (7).
We hypothesized that anticancer chemotherapeutics may 
inf luence the type of T cell–mediated immune responses 
induced by DCs by acting on immune inhibitory pathways. Here 
we demonstrate that platinum-based chemotherapeutics down-
regulate the inhibitory molecule programmed death receptor-
ligand 2 (PD-L2) in a STAT6-dependent manner, both on DCs 
and on tumor cells, resulting in enhanced T cell activation and 
increased tumor cell recognition. The clinical relevance of these 
observations is underpinned by our finding in head and neck 
cancer patients that tumor STAT6 expression is correlated with 
an improved clinical outcome when these patients received plat-
inum-based radiochemotherapy, but not when these patients 
were treated with radiotherapy only. These findings provide a 
rationale for the use of platinum-based chemotherapy in com-
bination with other immunostimulatory compounds to increase 
the clinical efficacy of cancer treatment.
Results
The T cell–stimulating potential of DCs is enhanced by platinum-based 
chemotherapy. We first determined the effect of a large number of 
clinically relevant concentrations of chemotherapeutic agents 
on the allogeneic T cell stimulatory potential of monocyte-
derived DCs (Supplemental Table 1; supplemental material 
available online with this article; doi:10.1172/JCI43656DS1). 
Surprisingly, DCs exposed to carboplatin during their matura-
tion by cytokines induced a significantly higher T cell prolifera-
tion compared with all other chemotherapeutics tested (Figure 
1A). We also observed this similar enhanced immune-stimulat-
ing activity in a dose-dependent manner for the platinum com-
pounds oxaliplatin and cisplatin, which are frequently used in 
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the clinic (Figure 1, B and C, and Supplemental Table 1). T cells 
that were activated by DCs exposed to platinum compounds 
produced significantly higher levels of IFN-γ and IL-2 compared 
with untreated DCs (Figure 1, D and E).
Notably, this increased T cell–stimulating activity of platinum-
treated DCs was also observed in antigen-specific T cells using 
keyhole limpet hemocyanin (KLH) as a model antigen (Figure 
2A). Moreover, we observed that the T cell stimulatory capacity 
of DCs matured in vitro through TLRs instead of cytokines was 
also further enhanced by platinum exposure (Figure 2A). The 
observed effect on TLR-DCs was not only limited to enhanced 
T cell proliferation but also supported by abundant IFN-γ pro-
duction by these antigen-specific T cells (Figure 2B). Although 
the platinum-induced immunogenic effect is more pronounced 
in TLR ligand–matured DCs, the background T cell proliferation 
and IFN-γ production is also more elevated when DCs were acti-
vated with TLR ligands. Therefore, we conclude that the observed 
effect of platinum compounds is independent from stimuli used 
to activate and/or mature DCs.
The enhanced immunogenicity of platinum-treated DCs is dependent on 
PD-L2/STAT6. To investigate why platinum-treated DCs display 
enhanced immunogenicity, we determined their phenotype (Fig-
ure 3A, shows effects of oxaliplatin; similar results were obtained 
with carboplatin and cisplatin, not shown). No significant differ-
ences were observed in expression of MHC class I and II or the 
costimulatory molecules CD80 and CD86 on platinum-treated 
versus nontreated DCs. Although we detected fluctuations in 
pro- and antiinflammatory cytokine production of DCs matured 
in the presence of platinum compounds (Figure 3, B and C, and 
Supplemental Figure 1), these differences were very small and not 
consistent for all platinum compounds, and they did not correlate 
with enhanced T cell activation. We therefore concluded that the 
enhanced immunogenicity is not caused by increased expression 
of MHC or costimulatory molecules or by increased proinflamma-
tory cytokine secretion upon platinum treatment.
Since DCs can also express several T cell inhibitory molecules, 
including PD-L1 and PD-L2, the enhanced T cell stimulatory 
potential upon platinum exposure could result from decreased 
PD-L expression. Indeed, treatment with oxaliplatin, cisplatin, 
or carboplatin during DC maturation moderately reduced the 
expression of PD-L1 and profoundly reduced the expression of 
PD-L2 (Figure 4A). We did not observe these effects with other 
tested chemotherapeutic agents. Expression of other known 
inhibitory receptors remained unaltered upon platinum treat-
ment (Figure 4B). Blocking of the PD-1/PD-L1/PD-L2 axis by 
anti–PD-L1 and –PD-L2 antibodies enhanced the capacity of 
Figure 1
DCs exposed to platinum-based chemotherapy display enhanced allogeneic T cell stimulatory capacity. (A) DCs were cultured in clinically 
relevant concentrations of chemotherapeutics during 48 hours of cytokine maturation and subsequently used in a mixed lymphocyte reaction 
with allogeneic PBMCs. T cell proliferation was measured by 3H-thymidine incorporation after 5 days. Ctrl, control DCs (nontreated); MTX, 
methotrexate; Cyta, cytarabine; Vinc, vincristine; Irino, irinotecan; Eto, etoposide; Bleo, bleomycin; DTIC, dacarbazine; Gem, gemcitabine; 
5-FU, 5-fluorouracil; Doxo, doxorubicin; Lena, lenalidomide; Carb, carboplatin. For all proliferation experiments, the statistical analyses were 
performed against the control unless otherwise specified in the figure; the mean of 6 replicates per experiment and the SEM are depicted. A 
representative experiment is shown. n = 3. **P < 0.01; ***P < 0.001. (B) Same experiment with different platinum-based chemotherapeutics. 
Oxali, oxaliplatin; cis, cisplatin. A representative experiment is shown. n = 3. (C) Concentration-dependent effect of platinum exposure on T cell 
stimulatory potential of DCs. This effect was observed irrespective of whether the platinum drugs were added during or after DC maturation 
(data not shown). Oxaliplatin concentrations 0.5, 2.0, 3.0, and 4.0 μg/ml. A representative experiment is shown. n = 5. (D and E) IFN-γ and IL-2 
secretion by T cells in MLR upon exposure to DCs cultured with or without platinum. A representative experiment is shown. n = 3. In the IL-2 
experiment, the P value was 0.07, but the difference may be important in a microenvironment of marked T cell proliferation and hence increased 
IL-2 consumption. Data are depicted as mean + SEM.
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mature DCs to stimulate T cells to a similar level when compared 
with platinum-treated DCs. However, the increased allostimula-
tory potential of DCs upon platinum treatment was abolished 
in the presence of PD-L2 antibodies (Figure 4C). This strongly 
supports the notion that downregulation of PD-L1, and particu-
larly PD-L2, is a major cause of the enhanced T cell stimulatory 
capacity of platinum-treated DCs.
The most important regulator of PD-L2 is the molecule STAT6. 
Macrophages from Stat6–/– mice are virtually unable to express PD-L2 
(8). DCs from NF-κB p50–/–p65–/+ mice also have defective PD-L2 
upregulation upon activation (9). Therefore, we measured STAT6 
and phosphorylated (active) STAT6 expression in DCs treated with 
or without platinum chemotherapy. We observed that treatment 
of DCs with platinum compounds resulted in a strong decrease 
in phosphorylated STAT6 (Figure 5A). To investigate whether the 
STAT6 dephosphorylation was the cause of the observed enhanced 
immunogenicity of DCs upon platinum exposure, we tested the T 
cell stimulatory activity of platinum-treated DCs exploiting siRNA 
against STAT6 (Figure 5B and Supplemental Figure 2). Despite 
the fact that inhibition was not complete, Stat6 knockdown DCs 
now lacked the previously observed enhanced T cell response upon 
platinum treatment, whereas DCs transfected with control siRNA 
still exhibited that response. To confirm that platinum-induced 
Stat6 dephosphorylation indeed mediated the observed PD-L2 
downregulation, we cultured bone marrow–derived DCs from 
Stat6–/– and wild-type BALB/C mice in the absence or presence of 
platinum chemotherapeutics (Figure 5C). We found that PD-L2 
was significantly more downregulated upon platinum exposure in 
wild-type DCs when compared with Stat6–/– DCs. Together, these 
data provide evidence that the enhanced immunogenicity of plati-
num-treated DCs depends on inactivation of STAT6 resulting in 
downregulation of PD-L2.
Platinum dephosphorylates STAT6 in tumor cells, resulting in decreased 
PD-L2 and subsequent increased T cell recognition. Since many cancer cells 
are capable of inducing an immunosuppressive microenvironment 
and upregulating PD-Ls in order to evade antitumor immunity (10), 
we next tested to determine whether the same platinum compounds 
also affected PD-L expression on tumor cells. To 
mimic an immunosuppressive microenviron-
ment in vitro, we exposed BLM melanoma cells to 
cytokine combinations known to induce PD-L1/2 
expression on endothelial cells, i.e., IL-4 together 
with IFN-γ, LPS, or TNF-α (11). Subsequent expo-
sure to platinum compounds clearly reversed PD-
L2 expression, but not PD-L1 expression (Figure 
6A and Supplemental Figure 3).
Because PD-L2 is regulated by STAT6 and NF-κB 
(8, 9, 12), we measured protein levels of STAT6 and 
phosphorylated (active) STAT6 in BLM tumor 
cells upon coculture with IL-4 and several NF-κB–
activating stimuli (Figure 6B and Supplemental 
Figure 4). We found that cisplatin caused a strong 
dephosphorylation of STAT6. Although several 
STAT molecules are constitutively expressed in 
multiple types of cancer and play an important 
role in the proliferative capacity and antiapoptotic 
and immune-evasive potential of cancer cells (13), 
a direct STAT-inactivating mechanism in cancer 
cells induced by clinically used cytotoxic chemo-
therapy has not been reported before.
To further explore whether chemotherapy-induced reversal 
of an immunosuppressive tumor microenvironment not only 
reduces PD-L2, but also effectively enhances susceptibility of 
tumor cells to cytotoxic T cells, we compared the recognition 
of platinum-treated and nontreated gp100 antigen expressing 
melanoma cells by gp100-specific T cells (14). As expected, we 
observed that platinum-induced reduction of PD-L2 coincides 
with enhanced T cell recognition as measured by antigen-specific 
IFN-γ production (Figure 6C). Together, these findings indicate 
that platinum compounds not only directly affect immune cells, 
but also modulate an immunosuppressive microenvironment by 
dephosphorylating STAT6 in tumors, resulting in downregula-
tion of PD-L2 and subsequent enhanced tumor cell recognition 
by cytotoxic T lymphocytes.
Tumor STAT6 dictates response to platinum-based cancer treatment. 
Finally, to verify the clinical relevance of platinum-induced 
STAT6 modulation in tumor cells in cancer patients, we analyzed 
tumor STAT6 expression in a cohort of patients with squamous 
cell carcinoma of the head and neck that had been treated in our 
institute with cisplatin in combination with radiotherapy (Figure 
7, A and B, and Supplemental Table 2). We could exclude a pos-
sible effect of radiotherapy on STAT6 activation by in vitro analy-
sis of IL-4–induced STAT6 phosphorylation in tumor cells, either 
irradiated or not (Supplemental Figure 5). After a median follow-
up of 68 months, we observed a clinically highly relevant and 
statistically significant difference between patients with STAT6-
negative tumors and STAT6-positive tumors with a 3-year recur-
rence-free survival of 48% and 80%, respectively (Figure 7C). In 
a matched cohort of patients that had been treated during that 
same period with radiotherapy only, tumor STAT6 expression 
was not correlated with an improved clinical outcome (Figure 
7D). Rather, there was a clear trend toward a shorter progres-
sion-free survival. This could be explained by the immune-eva-
sive potential of STAT6-expressing tumor cells, if not attacked by 
platinum-based chemotherapy. These data demonstrate the sig-
nificance of platinum-induced STAT6 modulation in the tumor 
microenvironment in cancer patients.
Figure 2
Enhanced T cell stimulatory potential of DCs matured with cytokines or TLR ligands 
in the presence of platinum chemotherapy in an antigen-specific model. (A) KLH-spe-
cific T cells were cocultured with KLH-loaded DCs, matured with cytokines or R848 and 
poly(I:C), in the presence or absence of platinum chemotherapy. cDC, cytokine-matured 
DCs; TLR-DC, TLR ligand–matured DCs; Ox, oxaliplatin. A representative experiment 
is shown. n = 3. (B) Enhanced IFN-γ secretion by T cells in MLR upon exposure to TLR 
ligand–matured DCs cultured with platinum as compared with platinum-untreated DCs. 
A representative experiment is shown. n = 3. *P < 0.05; **P < 0.01; ***P < 0.001. Data 
are depicted as mean + SEM.
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Discussion
Platinum-based chemotherapy represents a cornerstone in the sys-
temic treatment of many types of cancer (15). Recent observations 
suggest that, beside their direct cytotoxic effects, platinum antican-
cer drugs may also exert their clinical effect through indirect activa-
tion of the immune system via induction of an immunogenic type 
of tumor cell death (5, 6, 16). Furthermore, it has been reported that 
tumor sensitivity to T cell killing can be increased by platinum due 
to upregulation of tumor mannose-6-phosphatase receptors (17). 
Other examples of immunogenic effects of cancer chemotherapy 
include enhanced antigen presentation by gemcitabine, paclitaxel, 
and anthracyclines (3, 4); and enhanced homeostatic lymphocyte 
proliferation and specific tumor infiltration by cyclophospha-
mide (18). Depletion of myeloid-derived suppressor cells has been 
described for fluoropyrimidines (19), and depletion of regulatory 
T cells has been reported for cyclophosphamide (20). So far, the 
effect of cytotoxic anticancer drugs on inhibitory immunological 
pathways has not been described before.
The PD-1/PD-L pathway is of pivotal importance in regulating 
the immune balance between T cell activation and inhibition (10). 
High PD-L expression by antigen-presenting DCs can result in the 
induction of tolerant or anergic T cells (10, 21, 22). A wide variety 
of human cancers express PD-Ls, which are known to correlate 
with poor prognosis (23–26). Antibody blockade of the PD-1/PD-L 
pathway results in enhanced tumor-specific T cell expansion and 
activation (27, 28). Our findings show that treatment with plati-
num compounds downregulates these PD-L inhibitory molecules, 
which not only results in enhanced T cell stimulation by DCs, but 
at the same time enhances the sensitivity of the tumor for lysis by 
cytotoxic T cells. The importance of our findings is underscored by 
recent evidence that not only proinflammatory cytokines such as 
TNF-α (29), but also IL-4 and IL-13, are abundantly present in the 
tumor microenvironment and induce phosphorylation of STAT6 in 
tumor cells, resulting in an incompetent Th2 type of immune milieu 
(30). We propose that platinum-based chemotherapy may revert this 
incompetent Th2 into effective Th1 antitumor immunity.
While the results of this initial clinical study indicate that STAT6 
modulation is of major importance for the antitumor effect of plati-
num chemotherapy, a prospective trial is needed to truly assess the 
predictive value of STAT6 expression for tumor platinum sensitivity. 
In addition, we cannot exclude the possibility that besides PD-L2, 
other unknown factors in the tumor environment are affected by 
platinum-induced STAT6 dephosphorylation and may contribute to 
the observed effect. More research on the effects of platinum-induced 
STAT6 dephosphorylation is therefore warranted.
In conclusion, our findings may contribute to the design of 
innovative treatment schedules for cancer patients by the com-
bination of platinum compounds with known immunothera-
peutic approaches.
Methods
DC culture. Peripheral blood mononuclear cells were obtained from leuka-
pheresis material from melanoma and colorectal cancer patients participat-
ing in clinical DC vaccination studies (NCT00243529 and NCT00228189; 
http://clinicaltrials.gov/) (31, 32). The studies were reviewed and approved by 
our Institutional Review Board (Committee on Research Involving Human 
Subjects Region Arnhem-Nijmegen, Nijmegen, The Netherlands), and 
informed consent for experimental use of the cells was obtained from all 
Figure 3
Platinum compounds do not alter DC costimulatory molecule expression or cytokine secretion. (A) Expression of MHC class I and II, costimula-
tory molecules CD80, CD83, and CD86 by DCs exposed to 2.0 μg/ml oxaliplatin during maturation as compared with untreated mature DCs.
The MFIs of positive cells are shown as compared with platinum-untreated cells with SEMs, for 3 independent experiments for HLA class I and 
II and for 5 independent experiments for CD80, CD83, and CD86. (B and C) Production of proinflammatory cytokines TNF-α and IL-8 by DCs 
exposed to platinum chemotherapy during maturation. Supernatants were harvested 24 hours after stimulation. Means with SEMs of 3 separate 
experiments are shown. *P < 0.05; **P < 0.01. Data are depicted as mean + SEM.
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patients. DCs were generated from adherent peripheral blood mononuclear 
cells by culturing in X-VIVO 15 medium (Lonza) supplemented with 2% 
human serum (Sanquin) in the presence of IL-4 (500 U/ml) and granulocyte-
monocyte CSF (800 U/ml, both Strathmann), as previously described (33).
For experiments concerning KLH-specific immune responses, the DCs 
were loaded on day 3 of the culture with KLH (10 μg/ml; Calbiochem).
At day 5, DCs were matured with a cytokine cocktail (PGE2, 10 μg/ml 
[Pfizer]; TNF-α, 10 ng/ml, IL-1β, 5 g/ml, and IL-6, 15 ng/ml [all CellGe-
nix]) or with TLR3 and TLR7 ligands (poly[I:C], 20 μg/ml [Sigma-Aldrich]; 
and R848, 3 μg/ml [Axxora]) for 48 hours. Chemotherapy was added either 
after the maturation or during the maturation, as indicated. Supernatants 
were harvested after 24 hours for cytokine analysis.
Mixed lymphocyte reaction. DCs were plated in sterile 96-well U-bottom 
plates (Corning), 2 × 104/well in RPMI medium (Invitrogen), supplement-
ed with 5% human serum. Peripheral blood mononuclear cells of a healthy 
voluntary donor were freshly isolated by density gradient centrifugation 
and added to the wells, 1 × 105/well. Supernatants were harvested after 
48 hours for cytokine analysis, as indicated. After 5 days, 1 μCi/well of 
3H-thymidine was added to the culture for 8 hours, after which prolifera-
tion was stopped by storing the culture plate at –20°C. Incorporation of 
3H-thymidine was measured in a β-counter.
In some experiments, blocking antibodies against PD-L1 and PD-L2 
(both from eBioscience) were added to the culture in a final concentra-
tion of 10 μg/ml, as indicated. Normal mouse serum was used as isotype 
Figure 4
Platinum-based chemotherapeutics downregulate PD-L2 expression on DCs, resulting in enhanced T cell activation. (A and B) Expression of 
T cell inhibitory molecules PD-L1 and PD-L2 (light gray, isotype; white, untreated DC; dark gray, platinum-treated DC) and B7-H2/H3/H4 and IDO 
by DCs exposed to platinum chemotherapy during maturation. A representative experiment is shown. n > 5 for PD-Ls; n = 2 for other inhibitory 
molecules. (C) MLR with DCs matured in the presence (black bars) or absence (white bars) of 5 μg/ml oxaliplatin in the presence of blocking 
antibodies against PD-L1, PD-L2, or control immunoglobulin. #P < 0.05, compared with IgG control DCs; **P < 0.01; ***P < 0.001. A representa-
tive experiment is shown. n = 3. Data are depicted as mean + SEM.
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control. Antibodies against PD-L1 and PD-L2 were preincubated with the 
DCs for 30 minutes before adding the PBMCs.
Cytokine measurement and flow cytometry. Cytokine production was mea-
sured by cytometric bead array in the supernatants of the mixed lymphocyte 
reaction (MLR) (Th1/Th2 Cytokine CBA 1; BD Biosciences — Pharmingen 
or Flowcytomix BenderMed) or DC culture (Inflammation Kit CBA; BD 
Biosciences — Pharmingen or Flowcytomix, BenderMed).
Flow cytometry. The following antibodies were used for analysis of DC 
and tumor cell phenotype: HLA-ABC (hybridoma W6/32), HLA-DR/DP 
(hybridoma Q5/13), CD80, CD86, (all BD), CD83 (Beckman Coulter), PD-
L1-PE (eBioscience), PD-L2-PE, and IgG1-PE (both BD). The following 
antibodies were used for analysis of murine BM-DC phenotype: PD-L2–PE 
(CD 273, eBioscience), IgG2A-PE (eBioscience), CD11c-APC (Biolegend), 
and IgG1-APC (BD).
Tumor cell culture. The human melanoma cell line BLM was cultured in 
DMEM medium (Invitrogen) supplemented with penicillin G, streptomy-
cin sulfate, and amphotericin B (Invitrogen) and 7% human serum, in a 
concentration of 0.5 × 106 cells in T25 flasks or 1 × 106 cells in T75 flasks 
(Corning). Twice weekly, the cells were harvested and plated again at 1:10.
For PD-L expression upon platinum treatment, cells were cultured in 
the presence of oxaliplatin, carboplatin, and cisplatin in concentrations 
as indicated. After 24 hours, the cells were washed twice with PBS, after 
which trypsin (Invitrogen) was added for 30 seconds; this was then blocked 
with human serum–containing medium. Then the cells were harvested and 
analyzed by flow cytometry.
For phosphorylated STAT6/SHP-1 Western blot analysis, cells were 
activated for 30 minutes to 24 hours (as indicated) with IL-4 (300 U/ml; 
Strathmann) and/or IFN-γ (400 U/ml; Endogen) with or without 10 μg/ml 
cisplatin (added 15 minutes before the IL-4/IFN-γ). This was done in 5 ml 
medium in T25 flasks for each condition. After 30 minutes of activation, 
the cells were washed twice with PBS, after which trypsine (Invitrogen) was 
added for 30 seconds; this was blocked with the human serum-contain-
ing medium. Then the cells were harvested. For Western blot analysis, cells 
were washed twice in PBS, centrifuged at 300 g for 5 minutes, and lysed in 
ice-cold lysis buffer (see below).
In some experiments, BLM cells were harvested and subsequently irradi-
ated (30 or 60 Gy). Cells were plated in 6-well plates and stimulated with 
IL-4 for the indicated time points. STAT6 expression and phosphorylation 
were determined by Western blot (see below).
In vitro chemotherapy treatment. The chemotherapeutic agents that were 
used in the experiments are indicated in Supplemental Table 1. All drugs 
were used in clinically meaningful concentrations.
Transfection of siRNA against STAT6. siRNA (ON-TARGETplus) for the 
STAT6 gene was obtained from Dharmacon. In the case of DCs, approxi-
mately 1 × 106 immature monocyte-derived DCs were replated on day 3 in 
a well of a 24-well plate and transfected at day 5 with 2 μM siRNA and 6 μl 
DharmaFECT4 transfection reagent, essentially following the manufactur-
er's directions. Knockdown efficiency was assessed at the protein level by 
means of Western blot analysis. Cells were stimulated on day 6 with poly(I:C) 
and R848, and 48 hours after stimulation, these cells were used in mixed 
lymphocyte reactions, as described above.
Preparation of protein lysates and Western blotting. Regardless of cell type, 1 × 106 
cells were lysed in 100 μl phosphatase-inhibiting lysis buffer containing 
10 mM Tris/HCl, pH 7.8, 5 mM EDTA, 50 mM NaCl, 1 mM Na3VO4, 10 mM 
pyrophosphate, 50 mM NaF, 1% Triton X-100, 1 mM PMSF, 10 μg/ml 
aprotinin, 10 μg/ml leupeptin, and 1X Roche protease inhibitor cocktail 
(Roche Diagnostics Nederland BV). Before polyacrylamide gel electropho-
resis, reducing sample buffer (62.5 mM Tris/HCl, pH 6.8, 25% v/v glycerol, 
2% w/v sodium dodecyl sulfate, 0.01% w/v bromophenol blue, 5% v/v/β-
mercaptoethanol) was added 1:1 to a lysate equivalent of approximately 
200,000 cells. Samples were subjected to polyacrylamide gel electrophore-
sis using the Mini-PROTEAN system (Bio-Rad) and further processed for 
Western blot analysis (34). After blocking, membranes were incubated with 
one of the following antibodies: mouse monoclonal anti–β-actin (1:10,000; 
Sigma-Aldrich), mouse monoclonal anti-pSTAT6 (pY641, 1:250; BD Bio-
sciences — Pharmingen), or rabbit polyclonal anti-STAT6 antibody (S-20, 
Figure 5
Enhanced T cell activation by DCs 
upon platinum exposure is medi-
ated through STAT6 dephosphory-
lation. (A) Western blot analysis of 
cytokine-matured DCs treated for 24 
hours with 5 or 7.5 μg/ml cisplatin or 
oxaliplatin or medium during matu-
ration. Blot lanes were run on the 
same gel but were noncontiguous 
(white line). (B) MLR with DCs that 
were transfected with STAT6 siRNA 
or control siRNA and subsequently 
matured with or without 5 μg/ml oxali-
platin. A representative experiment 
is shown. n = 3. (C) PD-L2 expres-
sion of BM-derived CD11c+ IL-4/
LPS–stimulated DCs from wild-type 
and Stat6–/– BALB/c mice, cultured 
in the presence or absence of cis-
platin. Depicted are the normalized 
MFI and SEM of 1 of 2 independent 
experiments performed in triplicate. 
*P < 0.05; ***P < 0.001.
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1:500; Santa Cruz Biotechnology Inc.). After washing, the membranes 
were incubated with polyclonal goat anti-rabbit Alexa Fluor 680 (Molecu-
lar Probes) and goat anti-mouse IRDye 800CW (LI-COR Biosciences) as 
a secondary antibody, and analyzed with the LI-COR Odyssey Imaging 
system (LI-COR Biosciences). Integrated intensities were analyzed using 
Excel (Microsoft). Whenever necessary, membranes were stripped in 0.2 M 
glycine/1% w/v sodium dodecyl sulfate, pH 2.5, blocked, and reprobed and 
processed as described above.
Preparation and culture of murine wild-type and Stat6–/– DCs. Stat6–/– BALB/c 
mice were obtained from Charles River WIGA. They were kept under spe-
cific pathogen–free conditions in the animal facility of Radboud University 
Nijmegen Medical Centre. All animal experiments were approved by the 
Animal Experimental Committee of the Radboud University Nijmegen 
Medical Centre and were performed in accordance with institutional and 
national guidelines. For generation of bone marrow–derived DCs, bone 
marrow cells were prepared and cultured in BM-DC medium (Iscove’s 
modified DMEM, supplemented with 10% heat inactivated FCS, 50 mM 
β-mercaptoethanol) supplemented with 10 ng/ml recombinant mouse GM-
CSF. Fresh GM-CSF was given on day 3. Nonadherent and loosely adher-
ent clusters of proliferating DCs were harvested on day 6, resuspended 
in fresh BM-DC medium containing 10 ng/ml GM-CSF and 20 ng/ml IL-4, 
and matured by addition of 100 ng/ml LPS with or without cisplatin in 
6-well plates. After 24 hours, nonadherent DCs were harvested and the 
expression of PD-L2 on CD11c DCs was determined by flow cytometry.
Generation of CD8+ gp100-specific T cells. The vectors pGEM4Z-TCRα296 
and pGEM4Z-TCRβ296, a gift from N. Schaft (University Hospital Erlan-
gen, Erlangen, Germany), encode the TCR-α and -β chains originating 
from a gp100:280-288/HLA-A2–specific CTL clone (35). 
gp100-specific T cells were generated by transferring the 
TCR-α and -β chain to T cells by electroporation of RNA, 
resulting in transient expression of the TCR chains as 
described previously (36). Briefly, the DNA vectors were 
linearized with SpeI enzyme and purified by phenol/chloro-
form extraction and ethanol precipitation and used as DNA 
templates for in vitro transcription. In vitro RNA synthesis 
was done with T7 RNA polymerase (mMESSAGE mMA-
CHINE T7 kit; Ambion) according to the manufacturer’s 
instructions. After DNase treatment, RNA was purified by 
phenol/chloroform extraction and isopropanol precipita-
tion. RNA concentration was measured spectrophotometri-
cally, and RNA was stored at –20°C. RNA quality was veri-
fied by agarose gel electrophoresis.
CD8+ T cells were isolated from PBMCs of an HLA-A2.1–
positive donor. Monocytes were removed via adherence, and 
CD8+ T cells were isolated from the nonadherent cell population by posi-
tive isolation using FITC-conjugated anti-human CD8 (BD Biosciences) 
and anti-FITC microbeads (Anti-FITC Multisort Kit; Miltenyi Biotec) 
according to the manufacturer’s instructions.
For RNA electroporation, the CD8+ T cells were washed once with PBS 
and once with OptiMEM without phenol red (Invitrogen). 10 to 12 × 106 
cells were incubated for 3 minutes with 15–20 μg of RNA in 200 μl 
OptiMEM in a 4-mm cuvette (Bio-Rad). Subsequently, cells were pulsed 
in a Gene Pulser Xcell (Bio-Rad). Pulse conditions were square-wave pulse, 
500 V, 5 ms. Immediately after electroporation, the cells were transferred 
to X-VIVO-15 medium without phenol red (Cambrex) supplemented with 
2% human serum. After 4 hours incubation at 37°C, cells were washed and 
frozen in FCS and 10% DMSO in liquid nitrogen. Expression of the gp100 
TCR in the T cells was verified by flow cytometry using PE-conjugated 
anti-TCRVβ14 mAb (Coulter Immunotech), which recognizes the gp100 
TCR, the results of which we have reported previously (37). Functional-
ity of the gp100-specific T cells was shown by upregulation of the early 
activation marker CD69 after overnight stimulation with gp100:280–288 
peptide–loaded HLA-A2+ immature DCs.
gp100-specific activation of CD8+ T cells. For gp100-specific activation, 
BLM cells and BLM-gp100 (ref. 14) were activated for 20 hours with IL-4 
(300 U/ml; Strathmann) and/or IFN-γ (400 U/ml; Endogen) with or with-
out 5 μg/ml cisplatin (added 15 minutes before IL-4/IFN-γ). After 20 
hours of activation, BLM-gp100 or BLM (7 × 103 per well) was washed and 
coincubated with CD8+ gp100:280–288–specific T cells (5 × 104 per well) 
in round-bottom 96-well plates. After overnight incubation, IFN-γ pro-
duction was measured using a standard sandwich ELISA. gp100-specific 
Figure 6
Platinum-based chemotherapeutics downregulate PD-L2 
on tumor cells via STAT6 dephosphorylation, resulting in 
enhanced tumor cell recognition by tumor antigen–spe-
cific T cells. (A) PD-L1 and PD-L2 expression by BLM 
melanoma cells cultured in IL-4 and IFN-γ with or with-
out platinum chemotherapy for 24 hours. cis, 10 μg/ml 
cisplatin. A representative experiment is shown. n = 5. 
(B) Western blot of BLM melanoma cells treated with or 
without IL-4, IFN-γ, LPS, TNF-α, and 20 μg/ml cisplatin 
for 8 hours, as indicated. A representative experiment 
is shown. n = 5. (C) IFN-γ production of gp100-specific 
T cells upon coculture with gp100-expressing BLM mela-
noma cells, preincubated with or without 10 μg/ml cispla-
tin for 24 hours. A representative experiment is shown. 
n = 3. **P < 0.01. Data are depicted as mean + SEM.
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T cells produced no IFN-γ when cocultured with BLM melanoma cells 
that were not transfected with gp100 (not shown). The following Abs were 
used: coating Ab: mouse-IgG1-anti-hIFN-γ (clone 2G1; Pierce); detection 
Ab: biotinylated mouse-IgG1–anti-hIFN-γ (clone B133.5; Pierce). Strepta-
vidin-HRP and TMB were used as enzyme and substrate, respectively.
STAT6 staining of tumor sections. Paraffin-embedded slides of 58 patients 
with locally advanced squamous cell carcinoma of the head and neck that 
had been treated with cisplatin (weekly 40 mg/m2) in combination with 
accelerated radiotherapy were stained for STAT6 expression. Inflamma-
tory cells that stain for STAT6 were used as internal control. Percentage 
of tumor cells with cytoplasmic staining, regardless of intensity, was esti-
mated. Based on the distribution, 50% positive cells was chosen as cut-off 
level: tumors were considered STAT6-positive when more than 50% of the 
cells had cytoplasmic staining.
The staining procedure was as follows: slides were deparaffinized by 5-min-
ute incubation in xylol, washed in 100% ethanol, and hydrated in PBS. Slides 
were then incubated in 3% hydrogen peroxide for 10 minutes and hydrated in 
PBS. The slides were then placed in preheated to boiling temperature sodium 
citrate, 0.05%, pH 6, and incubated for 10 minutes and rinsed in 1× PBS. They 
were then incubated overnight with the primary antibody STAT6 diluted in 
normal antibody diluent (Immunologic) overnight at room temperature 
(dilution 1:80) at 4°C. The secondary antibody was PowerVision Poly-HRP–
Anti Ms/Rb/Rt IgG (Immunologic), which was used for 30 minutes at room 
temperature, followed by DAB (DAB plus, Power DAB) substrate for 5 min-
utes, and counterstained with hematoxylin and mounted with xylol.
Clinical study. We retrospectively constructed a patient database using data 
obtained in the period of 2000–2009 in our institute. Data were obtained 
from patients who received the standard of care treatment. These patients 
were informed that their clinical data and tissue samples could be used for 
anonymized scientific analysis, for which they gave their consent. Eligible 
patients had histologically proven locally advanced squamous cell carcino-
ma of the head and neck without distant metastases. We analyzed data from 
2 patient cohorts: one cohort of patients that had been treated with weekly 
cisplatin 40 mg/m2 in combination with a 6-week course of radiotherapy 
and a second cohort of patients that had been treated with radiotherapy 
alone. Histological tumor material for STAT6 staining obtained before 
treatment had to be available. The primary end point was recurrence-free 
survival, which was defined as the period between start of treatment and 
the occurrence of a relapse, not including a second primary or death due 
to other causes. The following characteristics were registered in the data-
base: tumor location, TNM stage, age, and sex (Supplemental Table 2). We 
collected data of 58 patients that had been treated with cisplatin in com-
bination with radiotherapy and of 48 patients, matched for tumor status, 
who had been treated with radiotherapy alone. Tumor and patient charac-
teristics were evenly distributed between STAT6-positive and STAT6-nega-
tive cases. Three patients were excluded: 2 patients because of inadequate 
tumor material for STAT6 staining, 1 patient because only material that 
was obtained after treatment was available.
Statistics. Data were analyzed statistically by means of ANOVA and 
Student-Neuman-Keuls test. Statistical significance was defined as 
P < 0.05. The recurrence-free survival curves were estimated by the 
Kaplan-Meier method and compared by means of the log-rank test. 
Data are depicted as mean + SEM.
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